mevinolinic acid: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
mevinolinic acid : A polyketide obtained by hydrolysis of the pyranone ring of lovastatin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 64727 |
| CHEMBL ID | 1201373 |
| CHEBI ID | 82985 |
| SCHEMBL ID | 1977672 |
| MeSH ID | M0193108 |
| Synonym |
|---|
| monacolinic k acid |
| l 154819 |
| 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-, (1s-(1alpha(betas*,deltas*),2alpha,6beta,8beta(r*),8aalpha))- |
| msd 803 free acid |
| l-154819 |
| msd 803 acid |
| mk 819 |
| 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)- |
| LVA , |
| (3r,5r)-7-((1r,2r,6s,8r,8as)-2,6-dimethyl-8-{[(2r)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-3,5-dihydroxyheptanoic acid |
| mevinolinic acid |
| lovastatin acid |
| DB03785 |
| (3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid |
| CHEMBL1201373 |
| chebi:82985 , |
| 7-[2,6-dimethyl-8-(2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid |
| unii-5clv35y90c |
| 75225-51-3 |
| 5clv35y90c , |
| (3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-{[(2s)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid |
| bdbm50406681 |
| (.beta.r,.delta.r,1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-((2s)-2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid |
| mk-819 |
| lovastatin impurity b [ep impurity] |
| hydroxyacid lovastatin [ep impurity] |
| 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-((2s)-2-methyl-1-oxobutoxy)-, (.beta.r,.delta.r,1s,2s,6r,8s,8ar)- |
| msd-803 acid |
| SCHEMBL1977672 |
| QLJODMDSTUBWDW-BXMDZJJMSA-N |
| C21130 |
| (3r,5r)-7-((1s,2s,6r,8r)-2,6-dimethyl-8-((s)-2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-3,5-dihydroxyheptanoic acid |
| DTXSID20873334 |
| Q24063271 |
| lovastatin hydroxy acid observed in lovastatin standard |
| HY-122439 |
| CS-0085508 |
| AKOS040746108 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the pharmacokinetic mechanisms contributing to its distinct efficacy and low side effects are unclear." | ( Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules. Aa, JY; Feng, D; Ge, C; Sun, JG; Tan, ZY; Wang, GJ; Xie, Y; Yan, CX; Yao, L, 2018) | 0.48 |
| Role | Description |
|---|---|
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor | Any EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme. |
| teratogenic agent | A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect. |
| drug metabolite | null |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| carbobicyclic compound | A bicyclic compound in which all the ring atoms are carbon. |
| dihydroxy monocarboxylic acid | Any hydroxy monocarboxylic acid carrying at least two hydroxy groups. |
| polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
| fatty acid ester | A carboxylic ester in which the carboxylic acid component can be any fatty acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 (µMol) | 4.0000 | 0.0500 | 2.3797 | 9.7000 | AID681366 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| organic anion transmembrane transporter activity | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| bile acid transmembrane transporter activity | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| prostaglandin transmembrane transporter activity | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| sodium-independent organic anion transmembrane transporter activity | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| thyroid hormone transmembrane transporter activity | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| basal plasma membrane | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| membrane | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| basolateral plasma membrane | Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID681381 | TP_TRANSPORTER: inhibition of calcein-AM efflux in MDR1-expressing MDCK cells | 2005 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4 | Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. |
| AID681366 | TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells | 2005 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4 | Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. |
| AID681370 | TP_TRANSPORTER: inhibition of calcein-AM efflux in MRP2-expressing MDCK cells | 2005 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4 | Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.70) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||